A maternal vaccine against group B Streptococcus: Past, present, and future

Vaccine

Volumn 31, Issue S4, 2013, Pages D13-D19

  Chen, Vincent L ^a,b   Avci, Fikri Y ^a,b   Kasper, Dennis L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Capsular polysaccharide; Glycoconjugate; Group B Streptococcus; Maternal; Mechanism; Reverse vaccinology

Indexed keywords

AMPICILLIN; BACTERIAL VACCINE; HAEMOPHILUS INFLUENZAE TYPE B CPS PROTEIN CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; CAPSULAR POLYSACCHARIDE; GLYCOCONJUGATE; IMMUNOGLOBULIN; OVALBUMIN; STREPTOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY TITER; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; GENOMICS; GROUP B STREPTOCOCCAL INFECTION; GROUPS BY AGE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MATERNAL MORTALITY; MORTALITY; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SPONTANEOUS ABORTION; STILLBIRTH; STREPTOCOCCUS AGALACTIAE; VACCINATION; CPS; DISEASE TRANSMISSION; FEMALE; GBS; GENITAL TRACT INFECTION; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MATERNAL; MECHANISM; MICROBIOLOGY; NEWBORN; NEWBORN DISEASE; OOCYTE; PREGNANCY; REVERSE VACCINOLOGY; STREPTOCOCCUS INFECTION; TT; INFANT, NEWBORN, DISEASES; STREPTOCOCCAL INFECTIONS; TRANSMISSION;

CAPSULAR POLYSACCHARIDE; CPS; GBS; GLYCOCONJUGATE; GROUP B STREPTOCOCCUS; IG; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY COMPLEX; MATERNAL; MECHANISM; MHC; OVA; OVALBUMIN; REVERSE VACCINOLOGY; TETANUS TOXOID; TT;

ANTIBODIES, BACTERIAL; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; POLYSACCHARIDES, BACTERIAL; PREGNANCY; REPRODUCTIVE TRACT INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 84883018187     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.080     Document Type: Review

References (57)

1. Paoletti L.C., Kasper D.L. Glycoconjugate vaccines to prevent group B Streptococcal infections. Expert Opin Biol Ther 2003, 3(6):975-984.
2. Hickman M.E., Rench M.A., Ferrieri P., Baker C.J. Changing epidemiology of group B Streptococcal colonization. Pediatrics 1999, 104(2):203-209.
3. Sendi P., Johansson L., Norrby-Teglund A. Invasive group B Streptococcal disease in non-pregnant adults - a review with emphasis on skin and soft-tissue infections. Infection 2008, 36(2):100-111.
4. Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., et al. Epidemiology of invasive group B Streptococcal disease in the United States, 1999-2005. J Am Med Assoc 2008 7, 299(17):2056-2065.
5. Stevens D.L., Kaplan E.L. Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis 2000, Oxford University Press, United States.
6. Lin F.Y.C., Weisman L.E., Troendle J., Adams K. Prematurity is the major risk factor for late-onset group B Streptococcus disease. J Infect Dis 2003, 188(2):267-271.
7. Palmeira P., Quinello C., Silveira-Lessa A.L., Zago C.A., Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Devel Immunol 2012, [Epub 2011 Oct; 2012:985646].
8. Leineweber B., Grote V., Schaad U.B., Heininger U. Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J 2004, 23(4):361-363.
9. Lin F.Y.C., Brenner R.A., Johnson Y.R., Azimi P.H., Philips J.B., Regan J.A., et al. The effectiveness of risk-based intrapartum chemoprophylaxis for the prevention of early-onset neonatal group B Streptococcal disease. Am J Obstet Gynecol 2001, 184(6):1204-1210.
10. Schuchat A. Group B Streptococcus. Lancet 1999, 353(9146):51-56.
11. Boyer K.M., Gotoff S.P. Prevention of early-onset neonatal group B Streptococcal disease with selective intrapartum chemoprophylaxis. N Engl J Med 1986, 314(26):1665-1669.
12. Baker C.J., Edwards M.S. Group B Streptococcal conjugate vaccines. Arch Dis Child 2003, 88(5):375-378.
13. Committee on Infectious Diseases Committee on Fetus Newborn Guidelines for prevention of group B Streptococcal (GBS) in infection by chemoprophylaxis. Pediatrics 1992, 90(5):775-778.
14. ACOG Group B streptococcal infections in pregnancy. ACOG technical bulletin number 170-July 1992. Int J Gynaecol Obstet 1993, 42(1):55-59.
15. Centers for Disease Control and Prevention Prevention of perinatal group B Streptococcal disease: a public health perspective. MMWR Recomm Rep 1996, 45(RR-7):1-24.
16. Schrag S.J., Zell E.R., Lynfield R., Roome A., Arnold K.E., Craig A.S., et al. A population-based comparison of strategies to prevent early-onset group B Streptococcal disease in neonates. N Engl J Med 2002, 347(July (4)):233-239.
17. Verani J.R., McGee L., Schrag S.J. Prevention of perinatal group B Streptococcal disease. Revised guidelines from CDC, 2010. MMWR Morb Mortal Wkly Rep 2010, 59(RR-10):1-31.
18. Schrag S., Gorwitz R., Fultz-Butts K., Schuchat A. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002, 51(August (RR-11)):1-22.
19. Gaschignard J., Levy C., Romain O., Cohen R., Bingen E., Aujard Y., et al. Neonatal bacterial meningitis 444 cases in 7 years. Pediatr Infect Dis J 2011, 30(3):212-217.
20. Fluegge K., Siedler A., Heinrich B., Schulte-Moenting J., Moennig M.J., Bartels D.B., et al. Incidence and clinical presentation of invasive neonatal group B Streptococcal infections in Germany. Pediatrics 2006, 117(June (6)):E1139-E1145.
21. Stevens J.P., Eames M., Kent A., Halket S., Holt D., Harvey D. Long term outcome of neonatal meningitis. Arch Dis Child 2003, 88(3):179-184.
22. Dagnew A.F., Cunnington M.C., Dube Q., Edwards M.S., French N., Heyderman R.S., et al. Variation in reported neonatal group B Streptococcal disease incidence in developing countries. Clin Infect Dis 2012, 55(1):91-102.
23. Rajagopal L. Understanding the regulation of group B Streptococcal virulence factors. Future Microbiol 2009, 4(2):201-221.
24. Avci F.Y., Kasper D.L. How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol 2010, 28:107-130.
25. Duan J., Avci F.Y., Kasper D.L. Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway. Proc Natl Acad Sci U.S.A. 2008, 105(13):5183-5188.
26. Kadioglu A., Weiser J.N., Paton J.C., Andrew P.W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008, 6(4):288-301.
27. Cieslewicz M.J., Chaffin D., Glusman G., Kasper D., Madan A., Rodrigues S., et al. Structural and genetic diversity of group B Streptococcus capsular polysaccharides. Infect Immun 2005, 73(5):3096-3103.
28. Slotved H-C., Kong F., Lambertsen L., Sauer S., Gilbert G.L., Serotype I.X. A proposed new Streptococcus agalactiae serotype. J Clin Microbiol 2007, 45(9):2929-2936.
29. Wessels M.R., Rubens C.E., Benedi V.J., Kasper D.L. Definition of a bacterial virulence factor-sialyation of the group B Streptococcal capsule. Proc Natl Acad U.S.A. 1989, 86(22):8983-8987.
30. Carlin A.F., Chang Y-C., Areschoug T., Lindahl G., Hurtado-Ziola N., King C.C., et al. Group B Streptococcus suppression of phagocyte functions by protein-mediated engagement of human Siglec-5. J Exp Med 2009, 206(8):1691-1699.
31. Baker C.J., Kasper D.L. Correlation of maternal antibody deficiency with susceptibility to neonatal group-B Streptococcal infection. N Engl J Med 1976, 294(14):753-756.
32. Castor M.L., Whitney C.G., Como-Sabetti K., Facklam R.R., Ferrieri P., Bartkus J.M., et al. Antibiotic resistance patterns in invasive group B Streptococcal isolates. Infect Dis Obstet Gynecol 2008, 2008:727505.
33. Borchardt S.M., DeBusscher J.H., Tallman P.A., Manning S.D., Marrs C.F., Kurzynski T.A., et al. Frequency of antimicrobial resistance among invasive and colonizing Group B Streptococcal isolates. BMC Infect Dis 2006, 6:57.
34. Baker C.J., Kasper D.L. Group-B Streptococcal vaccines. Rev Infect Dis 1985, 7(4):458-467.
35. Baker C.J., Edwards M.S., Kasper D.L. Immunogenicity from polysaccharides from type-III, group-B Streptococcus. J Clin Invest 1978, 61(4):1107-1110.
36. Eisenstein T.K., Decueninck B.J., Resavy D., Shockman G.D., Carey R.B., Swenson R.M. Quantitative determination in human sera of vaccine-induced antibody to type-specific polysaccharides of group-B Streptococci using a enzyme-linked immunosorbent assay. J Infect Dis 1983, 147(5):847-856.
37. Kasper D.L., Baker C.J., Galdes B., Katzenellenbogen E., Jennings H.J. Immunochemical analysis and immunogenicity of the type-II group-B Streptococcal capsular polysaccharide. J Clin Invest 1983, 72(1):260-269.
38. Fischer G., Horton R.E., Edelman R. Summary of the National Institutes of Health workshop on group-B Streptococcal infection. J Infect Dis 1983, 148(1):163-166.
39. Murphy K., Travers P., Walport M. Janeway's immunobiology 2011, Garland Science, New York.
40. Eskola J., Käyhty H., Takala A.K., Peltola H., Rönnberg P.R., Kela E., et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type B disease. N Engl J Med 1990, 323(20):1381-1387.
41. Avci F.Y., Li X., Tsuji M., Kasper D.L. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 2011, 17(12):1602-1609.
42. Avci F.Y., Li X., Tsuji M., Kasper D.L. Isolation of carbohydrate-specific CD4+ T cell clones from mice after stimulation by two model glycoconjugate vaccines. Nat Protoc 2012, 7(12):2180-2192.
43. Kasper D.L., Paoletti L.C., Wessels M.R., Guttormsen H.K., Carey V.J., Jennings H.J., et al. Immune response to type III group B Streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest 1996, 98(10):2308.
44. Hillier S, Ferris D, Fine D, Ferrieri P, Edwards M, Carey V. Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III (presentation). Annual meeting of the Infectious Diseases Society of America, Philadelphia, PA; 2009.
45. Paoletti L.C., Wessels M.R., Rodewald A.K., Shroff A.A., Jennings H.J., Kasper D.L. Neonatal mouse protection against infection with multiple group-B Streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun 1994, 62(8):3236-3243.
46. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000, 3(5):445-450.
47. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Arico B., Comanducci M., et al. Identification of vaccine candidates against serogroup B Meningococcus by whole-genome sequencing. Science 2000, 287(5459):1816-1820.
48. Sette A., Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010, 33(4):530-541.
49. Giuliani M.M., Adu-Bobie J., Comanducci M., Arico B., Savino S., Santini L., et al. A universal vaccine for serogroup B Meningococcus. Proc Natl Acad Sci U.S.A. 2006, 103(29):10834-10839.
50. Thigpen M.C., Whitney C.G., Messonnier N.E., Zell E.R., Lynfield R., Hadler J.L., et al. Bacterial meningitis in the United States, 1998-2007. N Engl J Med 2011, 364(21):2016-2025.
51. Harrison L.H., Trotter C.L., Ramsay M.E. Global epidemiology of meningococcal disease. Vaccine 2009, 27:B51-B63.
52. Rosenstein N.E., Perkins B.A., Stephens D.S., Lefkowitz L., Cartter M.L., Danila R., et al. The changing epidemiology of meningococcal disease in the United States 1992-1996. J Infect Dis 1999, 180(December (6)):1894-1901.
53. Maione D., Margarit I., Rinaudo C.D., Masignani V., Mora M., Scarselli M., et al. Identification of a universal group B Streptococcus vaccine by multiple genome screen. Science 2005, 309(5731):148-150.
54. Lauer P., Rinaudo C.D., Soriani M., Margarit I., Maione D., Rosini R., et al. Genome analysis reveals pili in group B Streptococcus. Science 2005, 309(5731):105.
55. Margarit I., Rinaudo C.D., Galeotti C.L., Maione D., Ghezzo C., Buttazzoni E., et al. Preventing bacterial infections with pilus-based vaccines: the group B Streptococcus paradigm. J Infect Dis 2009, 199(1):108-115.
56. Centers for Disease Control Prevention Active bacterial core surveillance report, emerging infections program network, group B Streptococcus, 2009 2010.
57. Centers for Disease Control Prevention Active bacterial core surveillance report, emerging infections program network, group B Streptococcus, 2010 2012.